Dimerix Past Earnings Performance

Past criteria checks 0/6

Dimerix's earnings have been declining at an average annual rate of -30.9%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 40.6% per year.

Key information

-30.9%

Earnings growth rate

-13.1%

EPS growth rate

Biotechs Industry Growth9.6%
Revenue growth rate40.6%
Return on equity-632.9%
Net Margin-119.2%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Is Dimerix (ASX:DXB) Using Too Much Debt?

Dec 19
Is Dimerix (ASX:DXB) Using Too Much Debt?

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Jul 05
We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Can Dimerix (ASX:DXB) Afford To Invest In Growth?

Feb 17
Can Dimerix (ASX:DXB) Afford To Invest In Growth?

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Sep 16
We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Jun 02
We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Sep 20
Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

May 17
Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Feb 01
Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Revenue & Expenses Breakdown

How Dimerix makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:DXB Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 239-11317
30 Sep 239-12319
30 Jun 239-14220
31 Mar 238-14219
31 Dec 226-14218
30 Sep 226-12216
30 Jun 226-10314
31 Mar 225-10213
31 Dec 214-9211
30 Sep 214-7210
30 Jun 214-629
31 Mar 213-618
31 Dec 202-617
30 Sep 202-516
30 Jun 202-416
31 Mar 202-415
31 Dec 191-414
30 Sep 191-413
30 Jun 191-313
31 Mar 191-313
31 Dec 181-313
30 Sep 181-323
30 Jun 181-322
31 Mar 181-322
31 Dec 171-321
30 Sep 171-221
30 Jun 171-211
31 Mar 171-211
31 Dec 161-211
30 Sep 161-311
30 Jun 161-511
31 Mar 160-510
31 Dec 150-510
30 Sep 150-310
30 Jun 150-110
30 Apr 140000

Quality Earnings: DXB is currently unprofitable.

Growing Profit Margin: DXB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: DXB is unprofitable, and losses have increased over the past 5 years at a rate of 30.9% per year.

Accelerating Growth: Unable to compare DXB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DXB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.7%).


Return on Equity

High ROE: DXB has a negative Return on Equity (-632.92%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.